Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease Posición conjunta de la Sociedad Española de Patología Digestiva y de la Sociedad Española de Farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal

Biological drugs or biopharmaceutical products, manufactured with or from living organisms using biotechnology, have represented a therapeutic revolution for the control of inflammatory bowel disease (IBD). At present, in this indication and in our country, only two biologicals are approved, inflixi...

Full description

Bibliographic Details
Main Authors:	Federico Argüelles-Arias, Manuel Barreiro-de-Acosta, Fernando Carballo, Joaquín Hinojosa, Teresa Tejerina
Format:	Article
Language:	English
Published:	Aran Ediciones 2013-01-01
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	Enfermedad inflamatoria intestinal Enfermedad de Crohn Colitis ulcerosa Biosimilares Infliximab Adalimumab Sociedad Española de Patología Digestiva Inflammatory bowel disease Crohn's disease Ulcerative colitis Biosimilairs Spanish Society of Gastroenterology
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000100006

Internet

http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000100006

Internet

Similar Items